Company news

Clarity Pharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Clarity signs copper-67 Supply Agreement with Nusano

October 16, 2025

Co-PSMA trial achieves primary endpoint

October 14, 2025

S&P DJI Announces September 2025 Quarterly Rebalance

September 5, 2025

Preliminary Final Report

August 28, 2025

Clarity successfully completes $203 million institutional pl

July 28, 2025

Co-PSMA trial: Recruitment successfully completed

July 17, 2025

Co-PSMA trial recruitment successfully completed

July 17, 2025

Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx

June 17, 2025

Clarity enters a Commercial Manufacturing Agreement

June 16, 2025

SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging

June 13, 2025

SABRE topline results

June 13, 2025

DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.

June 5, 2025

DISCO topline results

June 5, 2025

First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT

May 29, 2025

First patient imaged in Phase III AMPLIFY trial

May 28, 2025

Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences

May 20, 2025

AMPLIFY trial commences

May 20, 2025

Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano

April 17, 2025

Clarity signs commercial-scale copper-64 Supply Agreement

April 17, 2025

$11.1 million RDTI and refocus on high-priority programs

April 17, 2025

SECuRE trial update: First patient treated in the Phase II Cohort Expansion

April 15, 2025

First patient treated in the Phase II of the SECuRE trial

April 15, 2025

SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.

March 5, 2025

Clarity signs Cu-64 Supply Agreement with UQ

March 4, 2025

Appendix 4D

February 28, 2025

Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA

February 19, 2025

Clarity receives US FDA FTD for the treatment of mCRPC

February 18, 2025

Clarity expands pipeline with Cu-64/67 SAR-trastuzumab

February 10, 2025

Clarity to present COBRA and CLARIFY abstracts

January 27, 2025

Clarity receives U.S. FDA Fast Track Designation

January 23, 2025

Novel FAP-targeted radiopharmaceutical

December 17, 2024

S&P DJI Announces December 2024 Quarterly Rebalance

December 6, 2024

Last patient assessment completed for SARTATE trial

November 27, 2024

First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA

November 25, 2024

Chairperson Address AGM

November 19, 2024

Head-to-head IIT with SAR-bisPSMA

November 17, 2024

Clarity and Nucleus RadioPharma sign MSA

November 10, 2024

Copper-67 SAR-bisPSMA updates

October 15, 2024

Positive guidance from the US FDA on Phase III trial

October 13, 2024

Michelle Parker Promoted to CEO

October 13, 2024

Shareholder briefing - presentation

September 18, 2024

SECuRE trial advances

September 11, 2024

S&P DJI Announces September 2024 Quarterly Rebalance

September 6, 2024

FDA Fast Track Designation 64CU-SAR-bisPSMA

August 22, 2024

Supply agreement for Ac-225 with TerraPower Isotopes

July 15, 2024

Clarity strengthens Cu-64 network with new supply agreement

May 29, 2024

Complete response with Cu-67 SAR-bisPSMA

April 29, 2024

Successful Completion of Retail Entitlement Offer

April 24, 2024

Despatch of Retail Entitlement Offer Booklet

April 3, 2024

Completion of Placement and Institutional Entitlement Offer

March 27, 2024

← Newer news releases · Older news releases →

Decks

The 5 newest of 22 decks. Every deck is listed under its year.